Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Are GLP-1 Trials Measuring Nausea Well?

A 2026 review finds that major GLP-1 obesity trials recorded nausea without a validated, symptom-specific patient questionnaire.

Why we wrote this. Trial nausea rates look precise, but readers also need to know what the trials asked patients and what those counts leave out.

In this article (6 sections)
  1. What the review examined
  2. A safety report is not a symptom diary
  3. The contrast with quality of life
  4. What the finding does and does not mean
  5. What better nausea measurement needs
  6. Why this matters for GLP-1 evidence

A 2026 narrative review found a basic measurement gap in major GLP-1 obesity trials. The SCALE, STEP and SURMOUNT programmes recorded nausea as a spontaneously reported adverse event, entered by investigators and coded with the Medical Dictionary for Regulatory Activities (MedDRA). They did not use a validated questionnaire designed to capture the patient's experience of nausea[1]. That means the trials can tell us how often nausea was recorded, but they may describe its severity, timing and effect on daily life less well.

What the review examined

The paper, published online on 22 October 2026 in Diabetes, Obesity and Metabolism, reviewed how nausea was measured across three major obesity trial programmes: SCALE for liraglutide, STEP for semaglutide and SURMOUNT for tirzepatide. The authors compared those methods with COSMIN standards for selecting health measurement instruments and US Food and Drug Administration guidance on patient focused drug development[1][2].

This was a narrative review rather than a new randomized trial or a systematic estimate of nausea rates. Its question was narrower: when a participant felt nauseated, what process turned that experience into trial data? The authors report the same answer across the three programmes. Investigators recorded spontaneously reported adverse events and coded them in MedDRA, a standard vocabulary used to organize safety reports[1].

A safety report is not a symptom diary

Spontaneous reporting depends on a participant mentioning a symptom and on the study team recording it. MedDRA then gives that report a consistent label. That process is useful for pharmacovigilance, the work of detecting and tracking possible medicine related harms. The review argues that it was built for a different purpose from detailed symptom characterization[1]. A coded entry for nausea does not, by itself, show how intense the feeling was, how long it lasted or how much it disrupted meals and ordinary activity.

A patient reported outcome, often shortened to PRO, comes directly from the patient without an investigator interpreting the answer first. A symptom specific PRO can ask the same questions at planned intervals, using the same response scale. According to the review, none of the three programmes used a validated, nausea specific PRO instrument for this purpose[1]. The paper therefore identifies a gap in what the trials measured, not proof that every published nausea rate is wrong.

The contrast with quality of life

The review points to an unusual contrast. These trial programmes invested in structured quality of life measurement for obesity. They used the Impact of Weight on Quality of Life Lite Clinical Trials Version, alongside the Short Form 36 and EuroQol 5D instruments[1]. Nausea, although consistently the most documented adverse effect across the trials reviewed, did not receive the same symptom specific measurement approach[1].

That mismatch limits the questions a reader can answer from a trial table. A count of recorded events can support a comparison of how many participants had nausea entered in the safety data. It is less suited to comparing the burden of those events when the underlying experience was not collected with a dedicated, validated instrument. Two participants can share the same coded term while living through very different symptoms.

What the finding does and does not mean

The paper does not show that liraglutide, semaglutide or tirzepatide trials concealed nausea. It reports that all three programmes used a familiar adverse event surveillance method and did not add a validated nausea specific patient questionnaire[1]. Nor does a measurement gap establish that nausea alone causes people to stop treatment. The authors argue that the asymmetry may help explain why real world persistence falls short of what trial tolerability figures might lead readers to expect[1]. That is the review's interpretation, not a causal result from a trial.

The practical reading rule is modest. Treat a reported nausea percentage as the share of participants whose symptom became a coded adverse event under that trial's procedures. Do not automatically read it as a complete measure of symptom burden. Frequency, intensity and disruption are different questions, and one binary event count may not answer all three.

What better nausea measurement needs

The authors call for a fit for purpose metabolic nausea instrument, meaning a patient questionnaire designed and validated for nausea in this treatment setting. They argue that adverse event surveillance alone cannot provide the needed symptom characterization[1]. The abstract does not present a completed instrument or validation study. Developing one would require evidence that patients understand the questions, that the questions cover the experience being measured and that scores behave reliably enough for use in trials.

A dedicated measure would not replace ordinary safety reporting. The two methods answer different questions. Adverse event coding helps trials collect and classify possible harms across participants. A validated patient questionnaire could add a consistent account of the symptom itself. Used together, they could show both whether nausea was reported and what that nausea was like for the person reporting it.

Why this matters for GLP-1 evidence

Nausea is central to how readers judge the tolerability of GLP-1 based obesity medicines, yet the review found that its measurement lagged behind the trial programmes' work on obesity related quality of life[1]. Future trials can close that gap by pairing standard adverse event coding with a validated patient reported measure. Until then, nausea tables remain useful, but they should be read as records of reported events rather than full portraits of patients' symptom experience.

Frequently asked

How did major GLP-1 obesity trials measure nausea?

The review reports that SCALE, STEP and SURMOUNT relied on investigator-recorded, spontaneously reported adverse events coded with MedDRA. They did not use a validated questionnaire designed specifically to capture patients' nausea symptoms.

What is a patient-reported outcome measure?

It is a structured measure in which the patient reports symptoms or health effects directly, without an investigator interpreting the response first. A validated symptom measure uses tested questions and response scales.

Does the review say published nausea rates are wrong?

No. It identifies a measurement limitation. Trial rates describe nausea that was reported and coded under each study's safety procedures, but may not fully describe severity, timing or disruption to daily life.

Which GLP-1 obesity trial programmes did the review cover?

It examined liraglutide's SCALE programme, semaglutide's STEP programme and tirzepatide's SURMOUNT programme.

Sources

  1. [1]Oria and Darkhabani (2026): How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity TrialsTier 1 · primary↩
  2. [2]FDA Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome AssessmentsTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.